A share price of Unity Biotechnology Inc [UBX] is currently trading at $1.64, up 0.61%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UBX shares have gain 7.19% over the last week, with a monthly amount drifted -3.53%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, February 2024, New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss. In a post published today on Yahoo Finance, UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (DME). Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye. This can lead to fluid accumulation and retinal thickening – a key feature of DME. The study shows that the therapeutic clearance of senescent cells can potentially remove an underlying source of pathogenesis and thus allow healthy cells to regenerate and remodel retinal vasculature, ultimately leading to long-term disease modification.
From an analyst’s perspective:
Unity Biotechnology Inc [NASDAQ: UBX] stock has seen the most recent analyst activity on November 16, 2023, when Wedbush upgraded its rating to a Outperform and also boosted its price target to $4 from $2. Previously, ROTH Capital upgraded its rating to Buy on January 04, 2022. On November 10, 2021, upgrade upgraded it’s rating to Buy and revised its price target to $7 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $6 on June 28, 2021. H.C. Wainwright initiated its recommendation with a Buy and recommended $12 as its price target on June 07, 2021. Citigroup downgraded its rating to Sell for this stock on February 16, 2021, and upped its price target to $6. In a note dated August 18, 2020, Morgan Stanley downgraded an Equal-Weight rating on this stock but restated the target price of $5.
Unity Biotechnology Inc experienced fluctuations in its stock price throughout the past year between $1.46 and $3.82. Unity Biotechnology Inc [NASDAQ: UBX] shares were valued at $1.64 at the most recent close of the market.
Analyzing the UBX fundamentals
Gross Profit Margin for this corporation currently stands at 6.76% with Operating Profit Margin at 218.06%, Pretax Profit Margin comes in at 222.57%, and Net Profit Margin reading is 225.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -1.01 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5933 points at the first support level, and at 1.5467 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6733, and for the 2nd resistance point, it is at 1.7067.
Unity Biotechnology Inc [UBX] reported earnings per share of -$1.05 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.96/share, meaning a difference of -$0.09 and a surprise factor of -9.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.85 per share as compared to estimates of -$0.86 per share, a difference of $0.01 representing a surprise of 1.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Unity Biotechnology Inc [NASDAQ:UBX] is 5.74. Further, the Quick Ratio stands at 5.74, while the Cash Ratio is 0.91.
Transactions by insiders
Recent insider trading involved Ghosh Anirvan, Chief Executive Officer, that happened on Feb 02 ’24 when 680.0 shares were sold. Chief Executive Officer, Ghosh Anirvan completed a deal on Jan 30 ’24 to sell 1183.0 shares. Meanwhile, Chief Executive Officer Ghosh Anirvan sold 589.0 shares on Nov 02 ’23.
